Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual.
about
Diagnostic and prognostic prediction modelsCost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World DataEconomic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.Search filters for finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews.Sample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach.The D-Dimer test in combination with a decision rule for ruling out deep vein thrombosis in primary care: diagnostic technology update.Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the NetherlandsEconomic Evidence and Point-of-Care Testing.Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosisCost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.Effect of a public awareness campaign on the incidence of symptomatic objectively confirmed deep vein thrombosis: a controlled study.Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands.D-dimer testing for safe exclusion and risk stratification in patients with acute pulmonary embolism in primary care.Point-of-care tests in general practice: hope or hype?The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial.The cost-effectiveness of point-of-care D-dimer tests compared with a laboratory test to rule out deep venous thrombosis in primary care.Sneltests: hoop of hype?
P2860
Q26827577-32E3B93F-A6CE-4A99-BB9A-A8CDE648F653Q30985137-838AC1F3-19C1-4114-A053-916E19F71D8BQ34004770-4E1302C8-4FE3-4800-ADC1-E9D9D1462694Q34186027-D2ED14C8-72F1-4BBC-A870-D2C3179EBEE8Q35664152-46C0548E-5D84-408F-9934-B8A9CDE0A80CQ35916838-5EFFF765-B80C-4268-9CD6-7D122C7083CFQ36173045-12A81A9A-5522-440E-837B-99D1A7938DBBQ37236078-8B305EB5-7B4A-4D77-99E3-540C80548A89Q37508536-84C0D6A0-6572-498C-8C08-8D80BEFC42E5Q38042441-36461DAF-0564-4B8E-971E-D6AA7C7EA37DQ40061110-6E9CC6AA-AD9C-42B3-9AB2-DBE5B50FBE9BQ40196279-DC99D2C8-0B05-440E-B40B-3B7EB1EE98BAQ42063083-E6E9613E-A1F6-4BE7-BEDC-8AC584A38E20Q42697245-E6695AFC-6436-4EA1-B690-BD7EFAEAFC9BQ42869565-C6B22C60-7BFB-4248-AB6F-832D6B1E233EQ51022647-0F9128D9-8905-4F6B-B158-120F4FF91DBFQ57770839-ADD4B4E4-1455-47C1-A04C-A348E8EDF4E8
P2860
Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Cost-effectiveness of ruling o ...... ary care versus care as usual.
@en
Cost-effectiveness of ruling o ...... ary care versus care as usual.
@nl
type
label
Cost-effectiveness of ruling o ...... ary care versus care as usual.
@en
Cost-effectiveness of ruling o ...... ary care versus care as usual.
@nl
prefLabel
Cost-effectiveness of ruling o ...... ary care versus care as usual.
@en
Cost-effectiveness of ruling o ...... ary care versus care as usual.
@nl
P2093
P2860
P1476
Cost-effectiveness of ruling o ...... ary care versus care as usual.
@en
P2093
A J Ten Cate-Hoek
E F van der Velde
H C P M van Weert
H E J H Stoffers
H R Büller
K G M Moons
P2860
P304
P356
10.1111/J.1538-7836.2009.03627.X
P577
2009-09-28T00:00:00Z